U.S. markets closed

Santen Pharmaceutical Co., Ltd. (SNPHY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
12.63-0.27 (-2.09%)
At close: 3:50PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close12.90
Open12.78
Bid0.00 x 0
Ask0.00 x 0
Day's Range12.63 - 12.91
52 Week Range12.63 - 20.93
Volume45,775
Avg. Volume37,224
Market Cap5.117B
Beta (5Y Monthly)0.35
PE Ratio (TTM)16.51
EPS (TTM)0.76
Earnings DateN/A
Forward Dividend & Yield0.26 (2.05%)
Ex-Dividend DateSep 28, 2020
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Santen and TRACON Discontinue Development of DE-122 for Wet Age-Related Macular Degeneration

    Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; hereinafter, “Santen”) and TRACON Pharmaceuticals, Inc. (Head Office: San Diego, CA; hereinafter, “TRACON”) today announced the discontinuation of the development of DE-122 for the treatment of wet age-related macular degeneration (wAMD) following the review of recently obtained top-line data from the Phase 2a AVANTE clinical study. The Phase 2a AVANTE clinical study is a randomized controlled trial that assessed visual acuity in wAMD patients following six monthly treatments with a combination of DE-122 and Lucentis or single agent Lucentis. Topline data indicated that DE-122 did not improve visual acuity when combined with Lucentis as compared to single agent Lucentis treatment, the primary endpoint of the trial.